AI assistant
Innoviva, Inc. — Director's Dealing 2012
Aug 16, 2012
32090_dirs_2012-08-15_e2fde571-a695-4843-b79e-6e07777ee04c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2012-08-13
Reporting Person: Mammen Mathai (SVP, Research & Early Clin Dev)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-08-13 | Common Stock | S | 21892 | $25.68 | Disposed | 215393 | Direct |
| 2012-08-13 | Common Stock | S | 3108 | $26.15 | Disposed | 212285 | Direct |
Footnotes
F1: Dispositions made pursuant to a plan intended to comply with rule 10b5-1(c).
F2: This transaction was executed in multiple trades at prices ranging from $25.11 to $26.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $26.11 to $26.20. The price reported above reflects the weighted average sale price.